(EMAILWIRE.COM, January 03, 2017 ) The entire market for microvascular complications of diabetes (MCD) diabetic nephropathy, retinopathy, and neuropathy is facing an extremely high level of unmet need across the 7MM (US, 5EU and Japan). Despite its enormous potential, the MCD market is facing the major global barrier in the sparsely populated pipeline. The diabetic retinopathy segment of the market has recently seen rapid uptake of novel anti-VEGF therapies and is experiencing a strong growth. On the other hand, the diabetic neuropathy and nephropathy segments face the barrier in and increasing number of generic competitors.

The currently marketed product with the highest growth rate over the forecast period will be Regeneron/Bayers Eylea. Despite the drug still being in the pipeline for DME, it is being used off-label already. Its usage will drastically increase upon its approval for the DME indication in 2014.

Scope

Overview of MCD including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
Detailed information on the key drugs in the UK including product description, safety and efficacy profiles as well as a SWOT analysis.
Sales forecast for the top drugs in the UK from 2012-2022.
Analysis of the impact of key events as well the drivers and restraints affecting the UK MCD market.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=186891

Table of Content

1 Table of Contents 5
1.1 List of Tables 9
1.2 List of Figures 10

2 Introduction 11
2.1 Catalyst 11
2.2 Related Reports 12

3 Disease Overview 14
3.1 Etiology and Pathophysiology 16
3.1.1 Diabetic Nephropathy 16
3.1.2 Diabetic Retinopathy 18
3.1.3 Diabetic Neuropathy 19
3.2 Prognosis 20
3.3 Quality of Life 21
3.4 Symptoms 22

4 Disease Management 23
4.1 Treatment Overview 23
4.1.1 Diagnosis and Referrals 23
4.1.2 Screening 25
4.1.3 Treatment Guidelines 26
4.2 Japan 33
4.2.1 Diagnosis 33
4.2.2 Clinical Practice 35

For More Information Kindly Contact:

ResearchMoz
Mr. Nachiket Ghumare,
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG

Contact Information:
Researchmoz Global Pvt.Ltd
Researchmoz
Tel: +1-518-621-2074
Email us


----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results